Wall Street Zen Downgrades Aptevo Therapeutics (NASDAQ:APVO) to Sell

Aptevo Therapeutics (NASDAQ:APVO) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Aptevo Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Aptevo Therapeutics Price Performance

Aptevo Therapeutics stock opened at $4.51 on Friday. The company has a market cap of $4.51 million, a price-to-earnings ratio of 0.00 and a beta of 1.44. The firm has a 50-day moving average of $7.00 and a 200-day moving average of $17.86. Aptevo Therapeutics has a one year low of $3.95 and a one year high of $1,299.60.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Birchview Capital LP acquired a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $30,000. Birchview Capital LP owned approximately 1.32% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.